Abstract
Alpha-fetoprotein (AFP) is the primary marker for detecting hepatocellular carcinoma (HCC) and has been used widely in the clinic, but AFP is a biomarker characterized by poor sensitivity and specificity. Alpha-l-fucosidase (AFU) has been proposed as a tumor marker for diagnosis of HCC in many studies. However, conclusions of its diagnostic value are inconsistent. The current review aimed to evaluate the diagnostic value of AFU for HCC. After systematic review of 12 related studies, sensitivity, specificity, and diagnostic odds ratio (DOR) were pooled using random-effect models. Summary receiver operating characteristic (sROC) curve analysis was used to summarize the overall test performance. The pooled sensitivity for AFU was 0.72 (95 % confidence interval (CI) 0.69–0.76), while the pooled specificity was 0.78 (95 % CI 0.74–0.81). DOR was 10.26 (95 % CI 5.99–17.59), and the area under the curve (AUC) was 0.8125. AFU had great value for the diagnosis of HCC as a serum marker.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4(3):252–61.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 \ 1):S35–50.
Bertino G, Ardiri A, Malaguarner M, et al. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33.
Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39(4):434–9.
Ba MC, Long H, Tang YQ, Cui SZ. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol. 2012;5(9):874–81.
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16(4):418–24.
Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(8):1175–81.
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;10:3–25.
Whiting PF, Rutjes AW, Westwood ME. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
Chen K, Zhang H, Zhang LN, et al. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol. 2013;19(20):3143–9.
Wang JJ, Cao EH. Rapid kinetic rate assay of the serum alpha-l-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clin Chim Acta. 2004;347(1–2):103–9.
Ishizuka H, Nakayama T, Matsuoka S, et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-l-fucosidase activity. Intern Med. 1999;38(12):927–31.
Giardina MG, Matarazzo M, Morante R, et al. Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer. 1998;83(12):2468–74.
Hutchinson WL, Du MQ, Johnson PJ, Williams R. Fucosyltransferases: differential plasma and tissue alterations inhepatocellular carcinoma and cirrhosis. Hepatol. 1991;13(4):683–8.
Zheng T, Ren ZY. Activities of serum enzymes in patients with viral hepatitis B, posthepatitic cirrhosis and hepatocellular carcinoma. Chin Med J (Engl). 1990;103(9):729–34.
Yamamoto K, Yanagita T, Watanabe N, et al. The clinical significance of serum alpha-l-fucosidase assay in hepatocellular carcinoma. Fukuoka Igaku Zasshi. 1988;79(6):463–8.
Deugnier Y, David V, Brissot P, et al. Serum alpha-l-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology. 1984;4(5):889–92.
Bukofzer S, Stass PM, Kew MC, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. Br J Cancer. 1989;59(3):417–20.
El-Houseini ME, Mohammed MS, Elshemey WM, et al. Enhanced detection of hepatocellular carcinoma. Cancer Control. 2005;12(4):248–53.
El-Houseini ME. Serum alpha-l-fucosidase enzyme activity as a marker for hepatocellular carcinoma: comparison with AFU using ROC analysis. J Egyptian Nat Canc Inst. 2001;13:277–83.
El-Tayeh SF, Hussein TD, El-Houseini ME, et al. Serological biomarkers of hepatocellular carcinoma in Egyptian patients. Dis Markers. 2012;32(4):255–63.
Fawzy Montaser M, Amin Sakr M, Omar KM. Alpha-l-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol. 2012;13(1):9–13.
Giardina MG, Matarazzo M, Varriale A, et al. Serum alpha-l-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer. 1992;70(5):1044–8.
Hutchinson WL, Johnson PJ, Du MQ, et al. Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci (Lond). 1991;81(2):177–82.
Marotta F, Chui DH, Safran P, Zhang SC. Serum alpha-l-fucosidase. A more sensitive marker for hepatocellular carcinoma? Dig Dis Sci. 1991;36(7):993–7.
Shao Y. Union examination of AFP, AFU, AFPL3 and γ-GT in early diagnosis of primary liver cancer. Academic Journal of Xi’an Jiaotong University. 2009;21(3).
Takahashi H, Saibara T, Iwamura S. Serum a-l-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology. 1994;19(6):1414–7.
Tangkijvanich P, Tosukhowong P, Bunyongyod P, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30(1):110–4.
Zhu J, Jiang F, Ni HB, et al. Combined analysis of serum gamma-glutamyl transferase isoenzyme II, alpha-l-fucosidase and alpha-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med. 2013;5(1):89–94.
Troost J, van der Heijden MC, Staal GE. Characterisation of alpha-l-fucosidase from two different families with fucosidosis. Clin Chim Acta. 1976;73(2):329–46.
Zielke K, Okada S, O’Brien JS. Fucosidosis: diagnosis by serum assay of a-Lfucosidase. J Lab Clin Med. 1972;79(1):164–9.
Van Hoof F, Hers HG. The abnormalities of lysosomal enzymes in mucopolysaccharidoses. Eur J Biochem. 1968;7(1):34–44.
Elshemey WM, Desouky OS, Mohammed MS. Characterization of cirrhosis and hepatocellular carcinoma using low-angle x-ray scattering signatures of serum. Phys Med Biol. 2003;48(17):N239–46.
Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4(7):424–32.
Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20.
Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425C:212–20.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 24 kb)
Rights and permissions
About this article
Cite this article
Gan, Y., Liang, Q. & Song, X. Diagnostic value of alpha-l-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumor Biol. 35, 3953–3960 (2014). https://doi.org/10.1007/s13277-013-1563-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1563-8